Biogen Inc (BUE:BIIB)
ARS 18636 201.5 (1.09%) Market Cap: 28.98 Til Enterprise Value: 34.17 Til PE Ratio: 27.95 PB Ratio: 2.13 GF Score: 53/100

Biogen Inc at JPMorgan Healthcare Conference Transcript

Jan 08, 2024 / 07:15PM GMT
Release Date Price: ARS23696 (+6.47%)
Christopher Thomas Schott
JPMorgan Chase & Co, Research Division - Senior Analyst

So good morning, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be hosting a fireside chat today with Chris Viehbacher, who joined Biogen as CEO, I guess, a little bit over a year ago. So Chris, happy New Year. Thanks for joining us.

Christopher A. Viehbacher
Biogen Inc. - President, CEO & Director

Happy New year to you too, Chris.

Questions & Answers

Christopher Thomas Schott
JPMorgan Chase & Co, Research Division - Senior Analyst

Yes. So I think we were talking before. About a year ago, we were sitting in these same 2 seats. You had just come on as CEO. So I would love to start the conversation with just your reflections on how the last year has gone, anything that surprised you at a positive or negative in the CEO seat? And we'll kick off from there.

Christopher A. Viehbacher
Biogen Inc. - President, CEO & Director

Well, thanks, Chris. Yes,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot